Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.
Adlai Nortye Group (ANL) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ANL's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.
● GlobeNewsWireOct 27, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class AN4035 AN4035 is a nove…
● GlobeNewsWireOct 15, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial…
● GlobeNewsWireSep 30, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innova…
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Stock Has Consensus Target Price of $29.50 According to Analysts
Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ: ANL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the stock, MarketBeat.com reports. One …
● GlobeNewsWireSep 8, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with "Study-Ma…
Article counts from the last market-wide feed page, across every symbol we track and not just ANL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.